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Heparin is one of the most widely used drugs. It is used routinely 
for treatment and thromboprophylaxis in a broad spectrum of 
conditions including venous thromboembolism, atrial fibrillation, 
acute coronary syndromes, peripheral vascular disease and to 
maintain the patency of indwelling catheters and extracorporeal 
circuits. Heparin is one of the most frequently prescribed 
medications in the USA, where 12 million patients receive the drug 
annually.1
Thus clinicians and health care workers in virtually every branch 
of medicine may deal with patients who have received heparin 
in one of its forms. What follows is an overview of heparin and 
other rapidly acting anticoagulants. The discussion covers their 
pharmacology and addresses a serious complication of heparin 
therapy, namely heparin-induced thrombocytopenia (HIT). 
Pharmacology
Unfractionated heparin (UFH), derived from porcine intestine 
or bovine lung, is the prototype of a rapidly acting anticoagulant 
and has been used for over 60 years to arrest or prevent thrombus 
growth. It is a heterogenous mix of mucopolysaccharides with 
molecular weight varying from 3 000 to 30 000 Da which bind to 
and enhance the effect of the natural anticoagulant antithrombin 
III (AT).2 Heparin thus decreases available thrombin and other 
activated clotting factors (Xa, IXa, XIa, XIIa) effectively ‘switching 
off ’ the clotting cascade. Fig. 1 depicts the coagulation cascade. 
It has a rapid onset of action and is readily reversible, although it 
is highly protein bound, requiring careful laboratory monitoring 
of the activated partial thromboplastin time (aPTT). When 
administered at full intravenous dose, the aPTT should be kept at 
1.5 - 2.5 the control value.3 UFH may also be given subcutaneously 
at fixed dose for prophylaxis and treatment. 
The low molecular weight heparins (LMWH), e.g. enoxaparin 
(Clexane), with average molecular weights  of 5 000 Da, are 
manufactured from UFH and have superior dose-response 
relationships because of fewer nonspecific reactions with plasma 
proteins. They have high subcutaneous bioavailability (~90%) and 
allow fixed daily dosing according to body weight. In addition, they 
have less bleeding for a given antithrombotic effect and are at least as 
effective as UFH.3 Their use does not generally require monitoring 
and they are cleared renally. LMWH have less antithrombin activity 
than UFH and more inhibition of Xa.2 Different LMWH products 
vary in relative inhibition of factor Xa: thrombin.  LMWH can be 
given in therapeutic or prophylactic doses, but unlike UFH they 
cannot be fully neutralised by protamine. Thus if patients have high 
bleeding risks or if rapid reversal may be required, UFH is a safer 
option. Overall costs with LMWH are cheaper than intravenous 
UFH, because inpatient therapy with careful monitoring of aPTT is 
not required. Thus LMWH have allowed uncomplicated deep vein 
thrombosis (DVT) to be treated on an outpatient basis. 
LMWH levels cannot be monitored by the aPTT, but require 
a specialised anti-Xa assay, which is currently available at 
Johannesburg Hospital Haematology Laboratory (tel (011) 488-
3068). Monitoring is only required in special circumstances such as 
pregnancy, renal failure and obesity.4 See Table I for a comparison 
of unfractionated heparin and LMWH.
Fondaparinux (Arixtra) is a novel anticoagulant which takes 
the evolution of heparin even further. It is an indirect factor 
Xa inhibitor which does not cross-react with HIT antibodies.5 
Fondaparinux has shown to be at least as effective as LMWH in the 
treatment of venous thromboembolism and for thrombopophylaxis 
in a wide range of circumstances.6 Like LMWH, Fondaparinux 
has high biovailability, does not usually require monitoring and 
is administered subcutaneously. Importantly, Fondaparinux is 
not reversed by protamine sulphate.6 Fondaparinux is not yet 
commercially available for use in South Africa. 
Hirudin was the first parenteral anticoagulant used in humans 
in 1909,7 and is derived from the medicinal leech. Lepirudin is 
recombinant hirudin, and directly inhibits clot-bound thrombin, 
preventing its binding to fibrinogen. It thus prevents clot formation. 
Lepirudin has recently become available in South Africa as an 
alternative anticoagulant for patients with HIT. It is administered 
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Fig. 1. Simplified coagulation cascade for interpretation of in vitro  
testing.
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by intravenous infusion with monitoring 
by the aPTT (as per heparin), but unlike 
UFH it has no antidote. Hirudin is an 
expensive agent and is used with special 
permission only. Other anticoagulants not 
available in the local setting include the 
direct thrombin antagonist, argatroban, 
and the heparinoid danaparoid. 
Heparin-induced 
thrombocytopenia 
Heparin therapy may lead to HIT, which 
is paradoxically a prothrombotic state. It 
is one of the commonest and most serious 
of immune-mediated drug reactions.8 
The diagnosis is based on a high clinical 
index of suspicion. Laboratory testing is 
available in some referral centres in South 
Africa.  Appropriate management includes 
the immediate cessation of heparin 
therapy and the institution of appropriate 
alternative full-dose anticoagulation. 
Warfarin should not be administered in 
the acute setting and platelet transfusions 
are contraindicated.
Pathoph ysiology
HIT is caused by platelet-activating IgG 
antibodies that recognise complexes 
of heparin bound to a ‘self ’ protein, 
platelet factor 4 (PF4). Heparin induces 
a conformational change in PF4 which 
is recognised by the antibodies.9 The 
heparin/PF4/HIT-IgG complexes form 
on the platelet surfaces. This leads to in 
vivo platelet activation with associated 
thrombocytopenia and extension of 
existing thrombus or new venous/arterial 
thrombosis. Not all patients who develop 
the antibodies develop HIT. 
Incidence
Patients of any age receiving any form of 
heparin via any route may develop HIT, 
although the incidence is higher with UFH 
than LMWH: 3 - 5% of patients exposed 
to UFH for 5 days or more develop HIT 
during or after treatment.10 The incidence 
is much lower for LMWH (< 1%).11 Usually 
HIT occurs in patients given standard-dose 
heparin, but can be induced by minimal 
heparin exposure, e.g. heparin flushes 
used to maintain patency of indwelling 
venous and arterial lines. Surgical patients, 
particularly cardiac and orthopaedic 
patients have the highest incidence of HIT.11 
The condition is rare in obstetric patients. 
Unfortunately HIT is often unrecognised 
because thrombocytopenia is common 
in hospitalised patients for many other 
reasons, e.g. sepsis or sensitisation to drugs 
other than heparin. 
Clinical presentation
The time of onset of HIT varies according 
to the history of exposure. Classically 
the platelet count drops by > 50% from 
baseline between 5 and 10 days after initial 
exposure to UFH. However, in patients 
who have received heparin in the last 100 
days the onset is much quicker (hours) 
as these patients often have pre-existing 
antibodies. The thrombocytopenia is 
typically not severe and usually is 40 - 80 
x 109 /l.11 Note that the platelet count may 
drop by 50% from baseline and still be 
within the normal range. 
Bleeding is rare and the platelet counts 
typically recover within a week of ceasing 
heparin.
Diagnosis
If HIT is suspected, the probability of the 
condition should be judged on clinical 
grounds in the first instance. Four features 
are particularly helpful and a scoring 
system has been proposed to estimate the 
probability of HIT.12 This incorporates the 
‘4 Ts’: Thrombocytopenia + Thrombosis 
+ Timing + absence of oTher causes of 
thrombocytopenia (Table II).
The most common thrombotic 
complications are DVT and pulmonary 
embolism. The British Society for 
Haematology has produced practical, 
evidence-based guidelines for monitoring 
of platelet counts (Table III).13
The South African Society of Thrombosis 
and Haemostasis has provided guidelines 
for monitoring patients receiving 
prophylactic LMWH anticoagulation 
(Table IV).4
Laboratory tests for HIT are broadly 
classified into two categories – 
immunological assays (e.g. ELISA) which 
detect the antibody in the patient’s serum 
and functional assays which detect platelet 
activation in the presence of heparin. The 
immunological assays are generally used 
for screening and have high negative 
predictive values (i.e. a negative ELISA 
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Table I. Unfractionated heparin versus low molecular weight heparin
   UFH   LMWH
Molecular weight  3 000 – 30 000 Da  Mean 5 000 Da
Mechanism of action Increases antithrombin Greater anti-Xa: IIa activity
   activity > anti-Xa
Mode of administration IVI or SC   SC only
 Therapeutic dose  Bolus then IVI infusion  Fixed dose according to  
   with monitoring of aPTT body weight 
Monitoring  aPTT   Usually not necessary; anti- 
      Xa levels needed in renal  
      failure, severe obesity,  
      pregnancy 
Reversal   Reversed with IVI prota- Only partially reversible  
   mine sulphate  with protamine
Heparin-induced throm- 3 - 5%    < 1%
bocytopenia in those 
receiving therapy for 
≥ 5 days  
IVI = intravenous injection; SC = subcutaneous; aPTT = activated partial thromboplastin time.
Table II. Algorithm to assess likelihood of HIT (the 4 Ts)12
 2 points 1 point 0 point
Thrombocytopenia  > 50% fall or nadir  30 - 50% fall or < 30% fall or  
 of (20 - 100) x 109/l  nadir of (10 - 19)  nadir   
 (> 30% fall) x 109/l < 10 x 109/l
Timing consistent Yes (day 5 - 10); or  Possible (> day 10) No (< day 4) 
with HIT  < day 4 (recent  
 heparin) 
Thrombosis Yes Possible/silent No
OTher cuse for TPb No Possible Likely
High probability 6 - 8 points; moderate probability 4 - 5 points; low probability 0 - 3 points.
TPb = thrombocytopenia.
Reproduced with permission: Aster RH, Davoren A.11
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assay generally rules out HIT). However, 
false positives do occur and it is important 
to interpret the test in the appropriate 
clinical context.14 Limited laboratory 
testing is available in the South Africa.
Management
The British Society of Haematology has 
provided concise practical guidelines 
regarding management of HIT.13 For 
patients with strongly suspected HIT, 
heparin should be stopped and full-
dose anticoagulation with an alternative 
anticoagulant like lepirudin commenced. 
Alternatives available for the treatment of 
HIT include danaparoid and argatroban, 
although neither of these are available in 
South Africa Platelet transfusion should 
NOT be given as this may exacerbate 
the thrombosis, and warfarin should 
not be used until the platelet count has 
recovered. Warfarin may acutely increase 
the prothrombotic state due to dropping 
the protein C (natural anticoagulant) 
level. Vitamin K administration is 
recommended if warfarin has already 
started and investigation for lower limb 
DVT is advised. Specialist consultation 
with an experienced tertiary haematology 
centre should be instituted. 
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Table III. Recommendations for platelet count monitoring of patients 
on heparin treatment (British Society of Haematology)13
•   All patients who are to receive heparin of any sort should have a platelet count 
performed on the day of starting treatment
•   For patients who have been exposed to heparin in the last 100 days a baseline platelet 
count and a platelet count 24 hours after starting heparin should be obtained
•   For all patients receiving unfractionated heparin, alternate-day platelet counts 
should be performed from days 4 to 14
•   For surgical and medical patients receiving LMWH, platelet counts should be 
performed every 2 - 4 days from days 4 to 14
•   Obstetric patients receiving treatment doses of LMWH should have platelet 
counts performed every 2 - 4 days from days 4 to 14. Obstetric patients receiving 
prophylactic LMWH are at low risk and do not need platelet monitoring
•   If the platelet count falls by 50% or more and/or the patient develops new thrombosis 
or skin allergy between days 4 and 14 of heparin administration, heparin-induced 
thrombocytopenia (HIT) should be considered and a clinical assessment made
•   If the pretest probability of HIT is high, heparin should be stopped and an alternative 
anticoagulant started in full dosage while laboratory tests are performed, unless 
there are significant contraindications
Table IV. Recommendations for monitoring patients on LMWH (South 
African Society of Thrombosis and Haemostasis 2004)4
•   The patient’s platelet count should be checked on initiation of LMWH, after 5 days, 
and thereafter not less than once every 3 months, while on therapy
•  Anticoagulant activity is measured using an anti-Xa activity assay
•   Anti-Xa measurement is only indicated in pregnancy, renal failure or in excessively 
obese patients in whom large doses are required 
•  The anti-Xa assay must be calibrated for each LMWH tested
•   The anti-Xa assay is available for enoxaparin and nadroparin at Johannnesburg 
Hospital Haematology Laboratory, tel (011) 488-3068 or (011) 489-8552
•  5 ml citrated blood taken 3 hours after a LMWH dose is required for the assay
Target levels:
Prophylaxis target: 0.3 – 0.5 anti-Xa U/ml of blood
Therapeutic target: 0. 6 – 1.0 anti-Xa U/ml of blood
In a nutshell 
•   HIT is a common and serious immune-
mediated drug reaction.
•   Any form of heparin may cause the 
reaction.
•   The incidence is higher with UFH 
(~3%) than LMWH. 
•   Surgical patients are at highest risk, es-
pecially those who have had orthopae-
dic surgery.
•   The platelet count typically falls by 
> 50% 5 - 10 days after first exposure to 
heparin.  This occurs sooner in patients 
with previous heparin exposure.
•   The heparin-induced antibody com-
plex causes platelet activation, leading 
to thrombosis, usually venous. 
•   Half of those with HIT will develop as-
sociated thrombosis which has a high 
mortality rate.
•   A clinical scoring system (‘the 4 Ts’) is 
useful to make the diagnosis.
•   Appropriate management involves 
promptly ceasing heparin and institut-
ing full-dose alternative anticoagula-
tion. 
•   Warfarin should NOT be given in 
the acute setting as it may precipitate 
thrombosis, and platelet transfusions 
should be avoided.
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